View Agent
| Agent Info | |
| Agent: | nilotinib |
| Synonyms: | NIL;Nilotinibum;Tasigna;AMN 107;AMN107;AMN-107;Tasigna (Novartis);Nilotinib (INN/USAN);Nilotinib, AMN107, Tasigna;Tasigna, AMN-107, Nilotinib;L-1-yl)-3-(trifluoromethyl)phenyl]benzamide;Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-(9CI);4-Methyl-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide;4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazo;4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide;4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide;4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide;4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide;4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide |
| Drug Status For Certain Diseases: | Philadelphia chromosome positive CML(approved) |
| Classification: | a tyrosine kinase inhibitor structurally derived from imatinib that is approved in the United States for the treatment of chronic and acceleratedphase Philadelphia chromosome-positive chronic myelogenous leukemia in patients resistant or intolerant to prior therapy with imatinib. |
| Target: | Platelet-derived growth factor receptor Abl Mast/stem cell growth factor receptor |
| KEGG Pathway: | Axon guidance Acute myeloid leukemia Melanogenesis Hematopoietic cell lineage Central carbon metabolism in cancer Ras signaling pathway Endocytosis Viral myocarditis Chronic myeloid leukemia PI3K-Akt signaling pathway Rap1 signaling pathway Pathways in cancer Cytokine-cytokine receptor interaction Neurotrophin signaling pathway |
| Wiki Pathway: | Signaling by Robo receptor Integrated Pancreatic Cancer Pathway Apoptosis-related network due to altered Notch3 in ovarian cancer PIP3 activates AKT signaling Regulation of Microtubule Cytoskeleton ATM Signaling Pathway Kit receptor signaling pathway miR-targeted genes in epithelium - TarBase Factors involved in megakaryocyte development and platelet production Myogenesis Integrated Breast Cancer Pathway Pathogenic Escherichia coli infection Retinoblastoma (RB) in Cancer Fcgamma receptor (FCGR) dependent phagocytosis miR-targeted genes in muscle cell - TarBase Cardiac Progenitor Differentiation miR-targeted genes in lymphocytes - TarBase Differentiation Pathway Signaling by SCF-KIT |